Similarly, we identified proteins with known relevance to RCC like AXL, a target of cabozantinib, effective treatment for RCC77,78, and FBP1, a metabolic regulator frequently affected in clear cell RCC (ccRCC)66, highlighting how disrupted TF activity may drive downstream protein levels and oncogenic processes. The gene discussed is AXL; the disease is nonpapillary renal cell carcinoma.